Clinically meaningful improvement in PRO with risankizumab vs placebo in PsAAugust 21, 2022Psoriatic Arthritis
Nail dystrophy predicts response to secukinumab in PsA patients with axial manifestationsAugust 21, 2022Psoriatic Arthritis
Nail disease and dactylitis influence treatment response in patients receiving etanercept or methotrexateAugust 21, 2022Psoriatic Arthritis
Golimumab effective as second-line anti-TNFα treatment in the real-worldAugust 21, 2022Psoriatic Arthritis
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration formAugust 17, 2022Psoriatic Arthritis
Biosimilar-to-biosimilar switches deemed safe and effective, systematic review revealsAugust 15, 2022Psoriatic Arthritis
Study suggests psoriasis and PsA are underdiagnosed in underserved groupsAugust 12, 2022Psoriatic Arthritis
Commentary: Exercise, Mental Health, and Checkpoint Inhibitors in PsA, August 2022August 2, 2022Psoriatic Arthritis
Topical roflumilast approved for psoriasis in adults and adolescentsAugust 1, 2022Psoriatic Arthritis
